A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
Public ClinicalTrials.gov record NCT07729462. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, RANDOMIZED, 2-ARM STUDY TO INVESTIGATE THE PREVENTION OF CHRONIC MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN PARTICIPANTS 18 YEARS OF AGE OR OLDER
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine attacks in adults and for the preventive treatment of episodic migraine in adults when administered every other day. This study evaluates once daily rimegepant for the preventive treatment of chronic migraine. After a 28-day observation period without study intervention, eligible participants will be randomized in a 1:1 ratio to receive either rimegepant 75 mg orally disintegrating tablet (ODT) or matching placebo once daily for 12 weeks under double-blind conditions. Participants who remain eligible at the end of the double-blind treatment phase will enter a 12-week open-label treatment period, during which all participants will receive open-label rimegepant 75 mg once daily. During this period, participants may also take an additional rimegepant tablet for the acute treatment of breakthrough migraine attacks, up to 10 doses per month. A 28-day follow-up period completes the approximately 32-week study. The primary objective of the study is to determine whether once-daily rimegepant is more effective than placebo in reducing monthly migraine days relative to the observation period in adults with chronic migraine. Secondary objectives include evaluating differences between rimegepant and placebo in migraine responder rates, headache severity, acute migraine medication use, quality of life, work productivity, cognitive functioning, and safety and tolerability. Approximately 400 adults aged 18 years or older with a diagnosis of chronic migraine for at least 1 year will be enrolled at multiple study sites.
Study identification
- NCT ID
- NCT07729462
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 26, 2026 (Actual)
- Primary completion
- Oct 21, 2028 (Estimated)
- Completion
- Jan 19, 2029 (Estimated)
- Last update posted
- Oct 14, 2026
2026 – 2029
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Endpoints | Scottsdale | Arizona | 85258 | Recruiting |
| Hope Clinical Research | Canoga Park | California | 91303 | Recruiting |
| Neuro-Pain Research Center | Fresno | California | 93710 | Recruiting |
| Clinical Research Institute | Los Angeles | California | 90048 | Recruiting |
| Neurology Offices of South Florida PLLC | Boca Raton | Florida | 33428 | Recruiting |
| Conquest Research-Winter Park | Winter Park | Florida | 32789 | Recruiting |
| Josephson Wallack Munshower Neurology,PC | Indianapolis | Indiana | 46256 | Recruiting |
| Collective Medical Research | Overland Park | Kansas | 66212 | Recruiting |
| New England Regional Headache Center, Inc. | Worcester | Massachusetts | 01609 | Not yet recruiting |
| Michigan Headache & Neurological Institute | Ann Arbor | Michigan | 48104 | Recruiting |
| StudyMetrix Research | City of Saint Peters | Missouri | 63303 | Recruiting |
| Papillion Research Center / Avacare | Papillion | Nebraska | 68046 | Recruiting |
| Upstate Clinical Research Associates, LLC | Williamsville | New York | 14221 | Not yet recruiting |
| Hightower Clinical | Oklahoma City | Oklahoma | 73120 | Recruiting |
| Clinical Neuroscience Solutions, LLC. | Memphis | Tennessee | 38119 | Recruiting |
| FutureSearch Trials of Neurology | Austin | Texas | 78731 | Recruiting |
| Austin Clinical Trial Partners | Austin | Texas | 78737 | Recruiting |
| FutureSearch Trials of Dallas | Dallas | Texas | 75251 | Recruiting |
| Highland Clinical Research | Salt Lake City | Utah | 84124 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07729462, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07729462 live on ClinicalTrials.gov.